After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS
- Nasdaq, S&P stumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Citi Reiterates $7 PT on Cano Health (CANO), Says Takeout Could Be Worth $14 on Roughly 2x Revenue
September 23, 2022 12:18 PM EDTCiti analyst Jason Cassorla reiterated a Buy rating and $7.00 price target on Cano Health (NYSE: CANO).
The analyst comments "Another Takeout Headline Not Surprising: Multiple headlines over the past ~six months have suggested CANO could potentially be acquired. To this end, CANO traded at ~1.0x our 2023E revenue at an unaffected price of $6.31 (September 21st close), which compares to its SPAC merger multiple at ~3x forward revenue, and other recent deals in the space including AMZNs... More